Another CXCR4 antagonist, POL6326 has successfully completed Phase I clinical trials and is currently being investigated as a stand-alone therapy in a Phase II clinical trial for its efficacy in autologous transplantation of hematopoietic stem cells in multiple myeloma patients. The gene discussed is CXCR4; the disease is plasma cell myeloma.